

AMENDMENTS TO THE CLAIMS

1-4. (canceled)

5. (previously presented) A medical device configured to deliver a first and second drug to a blood vessel to reduce the degree or substantially prevent the occurrence of restenosis in the blood vessel, said first drug being epothilone D and said second drug being rapamycin or a rapamycin analog, wherein said first and second drugs show synergistic activity.

6. (currently amended) The medical device of Claim 5 wherein the medical device is a stent or polymer wrapper[.]

7-13. (canceled)

14. (previously presented) A composition comprising a polymer and a first and second drug, said first drug being epothilone D and said second drug being rapamycin or a rapamycin analog, wherein said first and second drugs show synergistic activity.

15-18. (canceled)

19. (previously presented) The composition of Claim 14 wherein the polymer is selected from the group consisting of a polylactide, a photo-curable poly(ester-amide), and a polyurethane.

20. (previously presented) A method to reduce the degree or substantially prevent restenosis in a blood vessel, comprising delivering a composition of Claim 14 to a blood vessel requiring treatment for, or prevention of, restenosis, in an amount sufficient to substantially reduce, or substantially prevent, restenosis in such blood vessel.